Sridevi Rajeeve MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Attending, Myeloma & Cell Therapy Service, Memorial Sloan-Kettering Cancer Center, NY
Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Rajeeve
Physician-investigator with a clinical and research interest in plasma cell dyscrasias (Multiple Myeloma, Precursor states - MGUS/SMM, Amyloidosis, Waldenstrom's Macroglobulinemia, POEMS Syndrome etc.), cellular therapeutics, clinical trials, digital health technologies and healthcare delivery transformation.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2020 - 2023- Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 2017 - 2020
Mahatma Gandhi UniversityClass of 2015, Bachelor of Medicine and Bachelor of Surgery (MBBS), Valedictorian
Certifications & Licensure
NJ State Medical License 2023 - 2027
NY State Medical License 2023 - 2027
PA State Medical License 2025 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Educational Commission for Foreign Medical GraduatesECFMG
Awards, Honors, & Recognition
- Domestic Scholar Award AIDS Malignancy Consortium
- Young Investigator Award (YIA) American Society of Clinical Oncology (ASCO), 2022
- HONORS Award and Grant American Society of Hematology (ASH)
Clinical Trials
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma Start of enrollment: 2024 Sep 03
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2023 Dec 05
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Start of enrollment: 2024 Aug 20
- Join now to see all
Publications & Presentations
PubMed
- Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, Aaron Mitchell, Ross S Firestone
JCO Oncology Practice. 2025-09-16 - Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance.Ross S Firestone, Anish K Simhal, Devin McAvoy, Eric M Jurgens, Juan-Jose Garcés
Clinical Cancer Research. 2025-08-25 - 3 citationsT-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy.Kai Rejeski, Jaime Sanz, Teng Fei, Monica S Nair, Hamza Hashmi
Blood. 2025-08-14
Abstracts/Posters
- Myelodysplastic Syndromes: Trends in Mortality, Costs of Hospitalizations, Length of Stay and Rate of ComplicationsSridevi Rajeeve, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic LeukemiaSridevi Rajeeve, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Acute Myeloid Leukemia and Cirrhosis: Trends in Utilization of Induction Chemotherapy, Rate of Hospitalizations and MortalitySridevi Rajeeve, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- European Hematology AssociationMember
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
